Related Experiment Video
Updated: Jun 22, 2025
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
Multiple nanotechnological approaches using natural compounds for diabetes management
Ozana Andreea Stoleru1, Ana Flavia Burlec1, Cornelia Mircea1
1Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Journal of Diabetes and Metabolic Disorders
|June 27, 2024
Summary
Plant-based nanoparticles offer a promising, eco-friendly approach to treating type 2 diabetes mellitus (T2DM). These nanoformulations enhance the delivery and effectiveness of natural compounds, improving patient outcomes and reducing treatment frequency.
Area of Science:
- * Endocrinology and Nanomedicine
- * Pharmacology and Drug Delivery Systems
Background:
- * Diabetes mellitus (DM) is a global endocrine disorder affecting approximately 400 million people.
- * Type 2 diabetes mellitus (T2DM) presents significant clinical challenges, necessitating innovative treatment strategies.
Purpose of the Study:
- * To review recent studies on the application of plant extracts and phytocompounds in nanotechnology for T2DM treatment.
- * To analyze the potential of nanoparticulate technologies in improving the delivery of natural antidiabetic agents.
Main Methods:
- * Comprehensive literature search across major scientific databases (Springer Link, Google Scholar, PubMed, Wiley Online Library, Science Direct).
- * Focus on studies investigating nanoparticulate drug delivery systems for phytocompounds in T2DM management.
Main Results:
- * Plant-based nanoformulations are highlighted as effective, eco-friendly, and cost-efficient for DM treatment.
- * Nanotechnology enhances drug delivery by improving targeted action, bioavailability, stability, and reducing dosage frequency.
- * Consideration of various drug delivery systems to minimize adverse effects of oral antidiabetic medications.
Conclusions:
- * Nanomedicine provides novel avenues for DM diagnosis, treatment, and prevention, showing improved outcomes for T1DM and T2DM.
- * Flavonoids (e.g., quercetin, naringenin, myricitrin) delivered via nanotechnologies demonstrate enhanced efficacy in preventing T2DM and its complications.
- * Future research should focus on developing nanostructured phytocompounds with superior bioavailability and therapeutic potential.
More Related Videos
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.5K
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.3K
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
01:24Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
01:25Insulin: Biosynthesis, Chemistry, and Preparation
372
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
372
01:22Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
01:06Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152